NVO FDA approves pluvicto for psma+ metastatic hormone-sensitive prostate cancer (mhspc), advancing potential new standard of Care across me
NVO FDA approves pluvicto for psma+ metastatic hormone-sensitive prostate cancer (mhspc), advancing potential new standard of Care across metastatic disease